Uriel Barkai, Ph.D. (GluSense Medical, Beta-O2) graduated from Tel-Aviv University in physiology of reproduction and extended his education at the Roche Institute of Molecular Biology (RIMB - Nutley, NJ) in cell and molecular biology. He was recruited to Tel-Aviv University and Serlin Maternity Hospital, where his research team developed techniques for human prenatal diagnosis and studied molecular cross talk between the uterus and the implanting embryo. Before moving to the biomedical industry in 1999, he spent a sabbatical in the Department of Physiology and Biophysics at the University of Illinois at Chicago. Dr. Barkai brings to the company more than 15 years of expertise in the biotechnology arena where he worked as director, manager, and consultant at numerous companies. Part of his work focused on molecular imaging (Spectrum Dynamics), wound healing (Polyheal), and clinical use of mesenchymal stem cells. In this area, he participated as founder (Bonus Biogroup) and CSO (Pluristem Therapeutics). Most of his efforts have focused on innovations in molecular diabetes. In this field, Dr. Barkai was a senior officer in three companies developing miniature and implanted cell-based glucose sensors (Carmel Biosensors, Glusense Medical, and Carmel StemSense). During the past 10 years he has been the CSO in Beta-O2 Technologies, Ltd where a bioartificial pancreas device is being developed that is based on stem cell derived beta cells.